Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 798

Results For "LA"

8967 News Found

USFDA expands use of Remdesivir  for Covid-19
News | January 22, 2022

USFDA expands use of Remdesivir for Covid-19

Previously, the use of the drug was limited to patients requiring hospitalization


Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
News | January 22, 2022

Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi

Omicron patients below 60 with no comorbidities can start treatment with paracetamol


Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study
News | January 21, 2022

Sputnik V demonstrates better protection compared to Pfizer against Omicron: Study

An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv


Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
Drug Approval | January 21, 2022

Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir

The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list


Bristol Myers Squibb receives approval for Abecma in Japan
Drug Approval | January 21, 2022

Bristol Myers Squibb receives approval for Abecma in Japan

It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021


US FDA approves Idorsia’s insomnia drug
Drug Approval | January 21, 2022

US FDA approves Idorsia’s insomnia drug

Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain


Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets
News | January 20, 2022

Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets

The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus


VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
Drug Approval | January 20, 2022

VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis

First launches expected in H1 2022


AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division
People | January 20, 2022

AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division

Ram’s appointment follows the launch of the CDI India division in October 2021.